Medco Health Solutions Inc

Medco Health Solutions — Accredo Health — Merger or Acquisition (March 2005)

40 slides from Medco Health Solutions's merger presentation, Mar 16, 2005

  1. Slide 1: Medco Health Solutions, Inc. at SG Cowen, March 16, 2005

    Filed by Medco Health Solutions, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Accredo Health, Incorporated Subject Company’s Exchange Act File No.: 0-25769 Medco 16, March Health 2005Sol

  2. Slide 2: Forward-looking statements

    Forward This results obligation together Exchange 2 presentation towith looking differ Commission. to publicly thematerially statements many contains update uncertainties from “forward-looking anythose forward-looking that set forth affect statements” inour the statement, business, statements. as th

  3. Slide 3: Medco strategy and strengths

    Medco Undisputed The Customer Innovation World Mail Medicare Clinical Pharmacy Specialty Technology Power Proven Stabilize World-Class Foundation Strong Client- 3 Independence Transparent Empowering Experience Class of Financial strategy Facing Drug Strategy Legal, Information Product Intimate Stage

  4. Slide 4: Medco delivered in 2004

    In 2004 Taking Nearly Ranked Wilson First Ernest Joint Medco’s Medco.com Customer No.4 February 4 PBM Commission Healthcare A. 1the Rx #1 Medco network million 2005 Codman Respect to lead inWebsite win customer delivered: on Company enrollees of national on Group Award the pharmacies ranked Accredit

  5. Slide 5: Medco delivered: strong financial results

    Medco vs 2004 $35.4 Mail 87.7 Net $481.6 $1.2 EBITDA/Adj. $1.83 Diluted + $2.14 (adj. Please EBITDA 5 3% 12% 13% 20% 22% 21% 2003 Revenue Income MM BN for Order BN see MM delivered: EPS intangible represents the Rx’s reconciliation Rx strong amort.) earnings financial of before non-GAAP results inte

  6. Slide 6: Medco: Significant financial strength

    Medco: With Significant Well Financial 6 positioned $21investment BN strength growth in to record –participate opportunities considerations strong renewals balance in Medicare in sheet, 2004, mail, generics focus cash-flow Part Donand top from specialty lineoperations growth pharmacy in and 2005trac

  7. Slide 7: Medco delivered: gross margin and efficiency

    Medco Gross vs 4.9% 3.9% 46.3% 4.4% Mail Total Productivity Generic 2004 2001 2002 2003 32.6% 34.0% 34.4% 38.5% 38.8% 40.5% 43.8% % 7 Adj. 2003 penetration rebates Margin delivered: Mail utilization Fill Rate and $3.0BN 38.8% efficiency increased % 46.3% +1.2% %+4.8 +2.5 profitability ptspts and eff

  8. Slide 8: Medco delivered: generic utilization and brand drugs going off patent

    Medco Brand ($ Generic On 2008 2007 2006 2005 2000 2001 2002 2003 2004 Duragesic® Effexor® 1.9 Nexium® Fosamax® 36.0% Ambien® 38.5% Pravachol® 40.5% Norvasc® Zoloft® 6.4 Zocor® 43.8% 9.6 46.3% 11.0 (Percent) Source: margin Changes 8 average, Drug delivered: IMS Dispensing may BN)Spend for Health occ

  9. Slide 9: Medco delivered: mail order growth and members

    Medco Members (MM Mail (Unadjusted, Express 2.2 Caremark 5.2 47 78 FEHBP 6.4 86 ~86 88 Q1 2004A 2005E 2003A 39 Source: 2003 2004 9 2005 Order Lives) delivered: Company Scripts inRxs Retail MM record Rx’s) reports. Refill mail Allowance Caremark volumePrograms results proforma for AdvancePCS acquisit

  10. Slide 10: Our clients: record renewals and new client wins

    Our clients Record Impressive Improved Focus 10 onnumber top-line client 2005 delivered: 2004 satisfaction new growth renewals client powerful in wins 2005 scores $21 vote $2.2 +BN of 20% BN confidence

  11. Slide 11: Medco focus: Medicare opportunity

    Medco Nearly 2004: Average 14% 56% 2005 Estimated Over Retail Generic Preparing 2006: Consulting Drug Dec June July Aug Sept Oct Nov $1.5 323 $18.7 $24.7 779 823 665 629 734 $41.5 $40.1 904 $42.8 $57.5 Members *Medco 11 Brand Generic 10 focus: Spend toone delivers: substitution million records Disco

  12. Slide 12: Medco delivers: Medicare Part D timeline 2005

    Medco May Prelim. January Final Solicitation August November PDP March Applications Bid June 4Q05 2Q05 1Q05 3Q05 February PDPs Bidders July Preliminary CMS December Medicaid April Risk Formulary September Acceptable Fallback 12 training ‘05 Contract premium enrollment ‘05 rates rule ‘05 establishes

  13. Slide 13: Medco delivers: support for employer clients on Medicare

    Medcoapproved Support CMS Health Assist Medicare Employer 13 employer Plans delivers: Medco Modernization Clients tools health multiple clients and plan inAct infrastructure Medicare continuing clients through channels to offer their &a traditional offerings Medicare Advantage retiree prescription p

  14. Slide 14: Medco delivers: specialty pharmacy growth

    Medco (MM 576 Drug Therapeutic Growth Cancer Immune Hepatitis Hemophilia Pulmonary MS Infertility Anemia 29.3 Rheumatoid 0.2 1.7 6.5 11.6 Jun Jan Jul Feb Over Source: 14 2003 2005 2004 customers 2003 125 Trend ofSpecialty delivers: Medco Hormone lives Deficiency drugs Hypertension for classes Arthri

  15. Slide 15: Definitive agreement to acquire Accredo

    Definitive Value $22 $2.2 Tax-free Accredo Customary Per Mid-2005 Consideration Transaction Conditions 15 Timing: share cash billion equivalent reorganization, stockholder and consideration: agreement regulatory to equity value: structure: .49107 closing: mix: tovalue; $43.33 shares approval toappro

  16. Slide 16: Acquisition creates largest specialty pharmacy

    Acquisition Specialty For Caremark Medco Priority $0 ~745 700 ~$1,500 1,700 $3,000 2,600 ~3,500 $4,500 4,200* *Combined Express Source: Accredo 16 the +12 Company Revenues months createsreports revenueended largest excludes 12/2004 and specialty dual-counted Wall(millions) Street pharmacy Equity scr

  17. Slide 17: Accredo: leading pure-play specialty pharmacy

    Accredo Therapeutic A Niche Medications Contracts 6 Revenues Other, Hemophilia A/1 Respiratory Syncytial (RSV), Primary Disease, Gaucher 36% Deficiency, Immuno- Disorders, Multiple Hormone Growth 17 15% Hypertension, 16% Arterial Sclerosis, Pulmonary months leading & product 12% 6% 6% company ending

  18. Slide 18: Accredo operates three service models

    Accredo One Hybrid HTC, Nurse/Pharmacist High Six Local Physician Hands Highest Fourteen Centralized Manufacturer Pharmacist Lower Differentiate 18 product product service DTC dispensing on service dispensing service operates product nursing &team &dispensing lines MC line model with sales MC model

  19. Slide 19: Accredo distribution and pharmacy locations

    Accredo Detroit Boston Minneapolis Seattle Iowa Salt Chicago San Las Philadelphia Omaha Washington, Denver St. Louisville Los Oklahoma Dallas/Ft. Atlanta Phoenix Birmingham New Jacksonville Nova Hemophilia Houston Memphis Charlotte Kansas Albuquerque Ft. Cincinnati Greensboro Newark Pittsburgh Nashv

  20. Slide 20: Combination leverages strengths of each entity

    Combination Limited Accredo Medco Reimbursement Manufacturer Niche Broad Dispensing Access Client 20 Scale Focus access Solutions toaccess Physicians Payors Automation leverages Solutions Expertise & Patients strengths of each entity

  21. Slide 21: Enhanced distribution access to specialty drugs

    Enhanced Distribution Source: A + Accredo Medco Status Provider Products ESI Caremark Clotting Cerezyme Botox Avonex Aralast Apokyn Aldurazyme Adagen Actimmune Priority CuraScript Growth Flolan Fabrazyme Enbrel 21 Zemaira Zavesca Xolair Tracleer Synagis restricted Remodulin Raptiva Prolastin exclusi

  22. Slide 22: Attractive financial characteristics and upside

    Attractive Top Upside Continued Expected Over Enhances 22 line $40 potential growth to million future financial growth be accretive opportunity, growth due inofcharacteristics expected to Medco robust opportunities to Medco specialty high annual pipeline margin inpre-tax 2006, business of business n

  23. Slide 23: Selected pro forma financial information

    Selected For Accredo ended (unaudited) Net EBITDA Debt/Total Debt/EBITDA $35.4 $1.2 $481.6 12/25/04 0.78 15 Medco 23 %the Revenue Income xBN <25 BN 12/25/04 12/31/04 1.45 MM Proposed twelve financial $154.6 Pro $1.7 %Capitalization x$76.1 Forma months BN MM Capitalization information MM 2004

  24. Slide 24: Medco

    medco

  25. Slide 25: Additional information

    Additional In Exchange obtain (http://www.sec.gov). Medco Accredo’s Memphis, Medco, stockholders stockholders, of SEC 25 connection stockholders. when free Health Accredo Commission TN, Investor they Information copies in dated with Solutions, 38134. respect become Additional and ofthe Relations Mar

  26. Slide 26: Use of supplemental non-GAAP measures

    Useincome, net supplemental not accepted must calculation Medco connection intangibles 26 represent ofbeNon-GAAP calculates uses considered accounting of with isand earnings funds ameasurement EBITDA useful cash the and Measures available in acquisition principles. flows per uses measure performing

  27. Slide 27: Reconciliation of adjusted net income per share

    Reconciliation Earnings Quarters Twelve Dec Net Adjustment 0.20 0.39 0.05 $1.57 $1.75 $0.43 Adjusted 0.10 27 $1.77 $2.14 $0.48 $0.58 Income 27, Months 25, 2003 2004 Ended per Netfor per Share Income Tables the Diluted Ended Amortization Reconciliation perShare Dilutedof Share Intangible Assets

  28. Slide 28: Reconciliation of adjusted EBITDA

    Reconciliation Quarters Twelve Dec Net Add $425.8 $481.6 $118.3 $132.8 Interest Provision 23.7(2) 59.9(1) 16.1 12.0 Depreciation 302.9 324.7 84.1 89.0 Amortization 189.0 197.6 49.9 39.9 Claims $1,035.7 $1,243.7 $292.0 $318.7 94.3 179.9 23.6 45.0 Prescriptions Mail Adjusted 532.0 502.9 137.7 125.9 To

  29. Slide 29: SG Cowen 25th Annual Health Care Conference Panel Discussion

    SG Robert Dr. Medco March Cowen 16, Health 2005 Epstein & Co. Solutions, 25th Annual Inc. Health Care Conference Panel Discussion

  30. Slide 30: Forward-looking statements

    Forward This results obligation together Exchange 2 presentation towith looking differ Commission. to publicly thematerially statements many contains update uncertainties from “forward-looking anythose forward-looking that set forth affect statements” inour the statement, business, statements. as th

  31. Slide 31: Overview of Medco's market and clients

    Overview >50% 100% Medco’s ~ 2004 Clients Rebate Network Purchase Medicaid/ Medco Other Express Caremark Captive Source: 3 60 million U.S. Net PBMs $200 spending agreements include centers PBMs Scripts Scale of and Revenues of Rx Medicare ~ BN members US including dispense 60,000 Spending advantage

  32. Slide 32: Plan designs: member cost sharing

    Plan Designs Member Deductibles Coinsurance Tiering Networks Mail Generics Source: 4 service –Medco cost –4–Member tier customized ––share 2005 separate copay split getting DataNew approaching in Pays on differentials various more for file twists Difference pharmacy common ways on30% old for themes

  33. Slide 33: Plan designs: newer ideas

    Plan Designs Reverse Reference Evidence-based OTC Consumer 5 coverage copays pricing directed 2005 formulary Newer health plan ideas tiering products – not much – drug traction aloneyet or combined

  34. Slide 34: Medco strength: scale in members and mail

    Medco Members (MM Mail (Unadjusted, Express 2.2 Caremark 5.2 47 78 FEHBP 6.4 86 ~86 88 Q1 2004A 2005E 2003A 39 Source: 2003 2004 6 2005 Order Lives) strength: Company Scripts inRxs Retail MMScale Rx’s) reports. Refill at mail Allowance Caremark Programs results proforma for AdvancePCS acquisition.

  35. Slide 35: Brand to generic opportunity

    Brand ($ Generic ~ 2008 2007 2006 2005 2000 2001 2002 2003 2004 Duragesic® Effexor® Nexium® 1.9 Fosamax® 36.0% Ambien® 38.5% Pravachol® 40.5% Norvasc® Zoloft® 6.4 Zocor® 43.8% 9.6 46.3% 11.0 (Percent) Source: Changes 7 $30 BN)BN Drug IMS opportunity Dispensing may in Spend branded Health occurComing

  36. Slide 36: Medicare drugs covered and excluded

    Medicare anorexia, Drugs all gamma chemotherapies total vaccines Off-label United DRUGDEX American 8 non parenteral excluded included States self-administered globulins uses weight vs. Hospital Medical Information Commercial Pharmacopeia-Drug nutrition loss, Association Formulary weight System injec

  37. Slide 37: Significant pipeline drugs 2005-2006

    Significant nebivolol Calmactin™ BiDil® exenatide Symlin® indiplon Myozyme® Preos® Acomplia™ Exubera™ Seasonique™ Alvesco™ lasofoxifene Pulminiq™ Dacogen™ Certican® Entereg™ Second First Revatio™ Retaane® Zarnestra™ Boniva® abatacept Ariflo® Xinlay™ febuxostat muraglitazar dapoxetine Nuvigil™ bazedo

  38. Slide 38: Full specialty drug pipeline

    Full Specialty Bay Xinlay™ Dacogen™ satraplatin CDP Preos™ Myozyme™ Retanne™ Lucentis™ sitaxsentan Revatio™ Beraprost ZD6474 Tirazone™ Age-related Arylsulfatase Revlimid™ Humira® Remicade® Rituxan® Abatacept Pulmonary Rheumatoid Pompe multiple Type orphan Osteoporosis Psoriasis Cancer saccharidosis

  39. Slide 39: Medco

    medco

  40. Slide 40: Additional information

    Additional In Exchange obtain (http://www.sec.gov). Medco Accredo’s Memphis, Medco, stockholders stockholders, of SEC 12 connection stockholders. when free Health Accredo Commission TN, Investor they Information copies in dated with Solutions, 38134. respect become Additional and ofthe Relations Mar

Accredo Health — Merger or Acquisition (March 2005) on 6ix